BTIG cuts target for Stryker stock to USD 316.00

Published on 10/13/2026 at 15:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue grew 9.40 percent. Stryker stock costs EUR 253.85 on October 13, 2026, minus 0.06 percent versus the Xetra close.

BTIG target cut and results date

On October 12, 2026, BTIG Research cut its target from USD 358.00 to USD 316.00.
Second-quarter revenue rose 9.40 percent to USD 6.59 billion.
Stryker stock costs EUR 253.85 at Lang & Schwarz on October 13, 2026 at 3:38 p.m. CEST, minus 0.06 percent versus the Xetra close of October 12, 2026.
Stryker is scheduled to report earnings on October 29, 2026.

Flatlay mit Aktienzertifikat, ISIN-Karte, Stethoskop und orthopädischem Implantatmodell — Flatlay-Arrangement mit Aktienzertifikat und ISIN-Karte US8636671013 illustriert eine Investition in Stryker Corp. Medizintechnik-Aktien, Illustration mit AI erstellt.

On October 12, 2026, BTIG Research lowered its Stryker target from USD 358.00 to USD 316.00 while maintaining a Buy rating, as MarketBeat reported. Against the USD 282.70 NYSE price at 9:51 a.m. ET on October 13, 2026, the new target lies 11.78 percent above the price. At Lang & Schwarz, Stryker stock was trading at EUR 253.85 on October 13, 2026 at 3:38 p.m. CEST, minus 0.06 percent versus the Xetra close of October 12, 2026 at EUR 254.00.

Revenue rebounds in second quarter

Stryker reported USD 6.59 billion of revenue in the second quarter of 2026, up 9.40 percent from the same period a year earlier, according to MarketBeat. Earnings per share reached USD 3.69, above the USD 3.49 consensus cited in the same October 12, 2026 report. The revenue comparison gives the analyst target cut a stronger operating backdrop, but it does not change the separate price calculation against the Xetra close.

Stock stays below its yearly high

The NYSE quote was USD 282.70 at 9:51 a.m. ET on October 13, 2026, while the 52-week range stood at USD 267.00 to USD 392.55. The price was 27.98 percent below the 52-week high, calculated from the same USD values.

Trading volume reached 256,816 shares at that timestamp, compared with an average volume of 2,614,159 shares. The gap between current volume and the average describes the session's activity without attributing a cause to the price move.

Valuation and reporting date

Stryker's market capitalization was USD 108.4 billion and its price-to-earnings ratio was 29.42 on October 13, 2026. The next earnings report is scheduled for October 29, 2026, after the market close, according to Gekko.

Comparison with peers

Stryker Corp. (NYSE, USD): minus 0.06 percent, P/E 29.42, market capitalization USD 108.4 billion

Medtronic (NYSE, USD): minus 0.32 percent, P/E 22.55, market capitalization USD 117.3 billion

Boston Scientific (NYSE, USD): minus 1.19 percent, P/E 17.61, market capitalization USD 64.4 billion

Price stays near EUR 254.00

The Lang & Schwarz quote placed Stryker at EUR 253.85 on October 13, 2026 at 3:38 p.m. CEST, minus 0.06 percent versus the Xetra close of October 12, 2026 at EUR 254.00. The primary listing is on the NYSE, where the stock was USD 282.70 at 9:51 a.m. ET on October 13, 2026.

The further course of trading is shown by the continuously updated real-time quote of Stryker stock.